LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect the company to announce earnings of ($0.91) per share and revenue of $3.0880 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

LENZ Therapeutics Stock Performance

Shares of LENZ opened at $12.15 on Monday. The firm has a market capitalization of $380.17 million, a price-to-earnings ratio of -5.76 and a beta of 0.52. LENZ Therapeutics has a one year low of $11.21 and a one year high of $50.40. The stock’s fifty day moving average is $15.01 and its 200-day moving average is $25.91.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LENZ. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of LENZ Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 1st. William Blair reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a research note on Tuesday, March 10th. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a report on Monday, December 15th. Finally, Zacks Research lowered shares of LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.40.

Institutional Trading of LENZ Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its stake in LENZ Therapeutics by 307.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,023,542 shares of the company’s stock valued at $16,378,000 after purchasing an additional 772,411 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in LENZ Therapeutics by 108.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company’s stock worth $32,907,000 after buying an additional 585,000 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of LENZ Therapeutics by 6,756.1% in the third quarter. Franklin Resources Inc. now owns 587,084 shares of the company’s stock valued at $27,346,000 after buying an additional 578,521 shares in the last quarter. Millennium Management LLC bought a new position in shares of LENZ Therapeutics in the fourth quarter valued at $8,630,000. Finally, Squarepoint Ops LLC lifted its position in shares of LENZ Therapeutics by 447.8% during the 4th quarter. Squarepoint Ops LLC now owns 491,898 shares of the company’s stock valued at $7,870,000 after acquiring an additional 402,110 shares during the last quarter. 54.32% of the stock is currently owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.